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BACKGROUND
The RTS,S/AS01 vaccine targets the circumsporozoite protein of Plasmodium falci-
parum and has partial protective efficacy against clinical and severe malaria dis-
ease in infants and children. We investigated whether the vaccine efficacy was 
specific to certain parasite genotypes at the circumsporozoite protein locus.
METHODS
We used polymerase chain reaction–based next-generation sequencing of DNA 
extracted from samples from 4985 participants to survey circumsporozoite protein 
polymorphisms. We evaluated the effect that polymorphic positions and haplo-
typic regions within the circumsporozoite protein had on vaccine efficacy against 
first episodes of clinical malaria within 1 year after vaccination.
RESULTS
In the per-protocol group of 4577 RTS,S/AS01-vaccinated participants and 2335 
control-vaccinated participants who were 5 to 17 months of age, the 1-year cumu-
lative vaccine efficacy was 50.3% (95% confidence interval [CI], 34.6 to 62.3) 
against clinical malaria in which parasites matched the vaccine in the entire cir-
cumsporozoite protein C-terminal (139 infections), as compared with 33.4% (95% 
CI, 29.3 to 37.2) against mismatched malaria (1951 infections) (P = 0.04 for differ-
ential vaccine efficacy). The vaccine efficacy based on the hazard ratio was 62.7% 
(95% CI, 51.6 to 71.3) against matched infections versus 54.2% (95% CI, 49.9 to 58.1) 
against mismatched infections (P = 0.06). In the group of infants 6 to 12 weeks of age, 
there was no evidence of differential allele-specific vaccine efficacy.
CONCLUSIONS
These results suggest that among children 5 to 17 months of age, the RTS,S vac-
cine has greater activity against malaria parasites with the matched circumsporo-
zoite protein allele than against mismatched malaria. The overall vaccine efficacy 
in this age category will depend on the proportion of matched alleles in the local 
parasite population; in this trial, less than 10% of parasites had matched alleles. 
(Funded by the National Institutes of Health and others.)
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Malaria induces substantial mor-bidity and mortality worldwide1 and has proved to be a challenge for vac-
cine-development efforts. The recently renewed 
effort to control, eliminate, and hopefully eradi-
cate malaria will have a greater likelihood of 
success if a vaccine can be combined with other 
intervention methods, such as drug-administra-
tion campaigns and insect-vector control.2,3 The 
most advanced candidate vaccine for protection 
against Plasmodium falciparum malaria infection, 
RTS,S/AS01, is a monovalent recombinant pro-
tein vaccine that targets a fragment of the cir-
cumsporozoite protein parasite antigen. RTS,S/
AS01 was evaluated in a large randomized, 
controlled, phase 3 trial, conducted at 11 study 
sites in Africa between 2009 and 2013, in which 
the efficacy, safety, and immunogenicity of the 
vaccine was assessed in more than 15,000 chil-
dren. The vaccine confers moderate protective 
efficacy against clinical disease and severe ma-
laria that wanes over time,4-7 a finding concor-
dant with results of multiple phase 2 trials.8-13 
Higher protection was observed among young 
children (5 to 17 months of age at first vaccina-
tion) than among infants (6 to 12 weeks of age 
at first vaccination).4-7
The mechanism by which the vaccine confers 
protection is incompletely understood, and dif-
fering hypotheses exist regarding the relative im-
portance of B-cell–mediated versus T-cell–medi-
ated immunity to circumsporozoite protein and 
other antigens.14-17 The circumsporozoite protein 
is expressed on the surface of the parasite dur-
ing the infective sporozoite stage and contains a 
conserved NANP–NVDP tandem repeat with a 
length polymorphism ranging from 37 to 44 
repeat units,18 which is thought to represent the 
dominant B-cell epitope.19 There are numerous 
polymorphisms within the C-terminal region of 
circumsporozoite protein,18,20-22 some of which 
reside within described T-cell epitopes (Th2R 
and Th3R)23 that may also function as B-cell 
epitopes.24 Although the immune response pro-
voked by RTS,S/AS01 may be distinct from the 
natural response to circumsporozoite protein,25,26 
the partial protective efficacy of the vaccine may 
be due in part to allelic specificity. Evidence of 
naturally acquired allele-specific immunologic 
protection has been observed for the merozoite 
surface protein 1 antigen27 (but not circumspo-
rozoite protein28) in a prospective cohort study, 
and allele-specific protection has been reported 
in a field trial of a vaccine based on apical mem-
brane antigen 1.29
Previous genetic analyses of parasite samples 
from three different RTS,S phase 2 studies did 
not detect an association between protective ef-
ficacy and the genetic similarity of the parasite 
to 3D7 (the vaccine construct parasite line)30-32; 
however, our study has both a larger sample and 
improved sequencing technology. Next-genera-
tion sequencing (Illumina MiSeq, PacBio) of 
polymerase-chain-reaction (PCR) amplicons ob-
tained from samples from malaria-infected par-
ticipants makes a more sensitive genetic investi-
gation of allele-specific protection possible and 
allows for more immunologically relevant analy-
ses of multivariant haplotypes. Using sieve-
analysis methods (Fig. S1 in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org) that have previously been ap-
plied to the detection of allele-specific vaccine 
efficacy against human immunodeficiency virus 
type 1,33,34 we analyzed the relationship between 
vaccine efficacy, in two age categories with regard 
to two defined trial end points, and the parasite 
circumsporozoite protein at three levels: the entire 
C-terminal amplicon haplotype (95 amino acids), 
defined haplotypic regions of the C-terminal 
(10 to 17 amino acids), and individual polymor-
phic positions. We also investigated the relation-
ship between vaccine efficacy and NANP–NVDP 
repeat count, and we included the serine repeat 
antigen 2 (SERA-2) locus as a control; SERA-2 
was not in the vaccine, and therefore no differ-
ential efficacy was expected with regard to the 
parasite genotype at this locus.
Me thods
Study Design and Sequence-Data Generation
The RTS,S phase 3 trial design has been de-
scribed previously (for details, see ClinicalTrials 
.gov number NCT00866619).4-7 Samples were 
analyzed from vaccine recipients at all 11 trial 
sites, spanning seven countries in Africa (Fig. 1A). 
Samples representing two protocol-specified end 
points were sequenced in the per-protocol co-
hort (i.e., participants who received all three 
vaccinations at months 0, 1, and 2): primary 
clinical malaria (first or only episode of clinical 
malaria with a parasite density >5000 per cubic 
millimeter), occurring between 14 and 385 days 
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after the third vaccination, and parasite positiv-
ity (parasite density >0 per cubic millimeter, re-
gardless of whether symptoms were present), 
occurring at 18 months after vaccination.3
Samples from participants were received as 
dried blood spots on Whatman FTA sample 
cards. The methods we used for DNA extraction, 
PCR amplification, and sequencing are described 
in the Supplementary Appendix. The circumspo-
rozoite protein C-terminal and SERA-2 ampli-
cons were sequenced on an Illumina MiSeq 
platform. The NANP–NVDP amplicon was se-
quenced on a PacBio platform because of its 
greater length. Fig. 1A shows the respective lo-
cations of the NANP–NVDP repeat region and 
C-terminal amplicon within the circumsporozo-
ite protein. The analyses included MiSeq data for 
4421 circumsporozoite protein C-terminal sam-
ples and 4499 SERA-2 samples and PacBio data 
for 3137 circumsporozoite protein NANP–NVDP 
samples (Tables S1 through S4 and the statisti-
cal analysis plan in the Supplementary Appen-
dix). All MiSeq and PacBio amplicon sequence 
data were submitted to the NCBI Sequence Read 
Archive35 (BioProject PRJNA235895).
 Study Oversight
The trial was sponsored by GlaxoSmithKline Bio-
logicals, the developer and manufacturer of the 
vaccine, and was funded by both GlaxoSmith-
Kline Biologicals and the PATH Malaria Vaccine 
Initiative, which received a grant from the Bill 
and Melinda Gates Foundation. Several of the 
academic authors, in collaboration with the four 
authors who are employed by GlaxoSmithKline 
Biologicals, designed the study and the analysis 
plan. Several of the academic authors collected 
the data, wrote the manuscript, and vouch for 
the accuracy and veracity of the reported data, 
and the first and last authors made the decision 
to submit the manuscript for publication. Glaxo-
SmithKline Biologicals reviewed the manuscript 
before it was submitted for publication. Addi-
tional details regarding author contributions are 
provided in the Supplementary Appendix. The 
trial protocol was approved by all relevant ethics 
review boards, and written informed consent, 
indicated with either a signature or a thumb-
print, was obtained from the children’s parents 
or guardians.4-7
 Statistical Analysis
The analyses that were prespecified for this 
study are described in the statistical analysis 
plan (see the Supplementary Appendix). In brief, 
we performed sieve analyses of translated amino 
acid sequences to assess differences in vaccine 
efficacy with respect to the end points of first or 
only episodes of clinical malaria and parasite 
positivity, according to whether the parasite was 
a match or a mismatch with the 3D7 vaccine 
strain at the circumsporozoite protein C-terminal 
and according to the number of NANP–NVDP 
repeats present. We refer to differential vaccine 
efficacy according to a given parasite feature as 
a “sieve effect.” For the primary analysis of clini-
cal malaria, two haplotype-specific measures of 
vaccine efficacy were assessed: cumulative vac-
cine efficacy, which is defined as one minus the 
ratio (RTS,S/AS01 vs. control) of cumulative inci-
dences of the first or only episode of clinical 
malaria with a specific haplotype by a given num-
Figure 1. Study Sites and Genomic Units.
A Study Sites B Circumsporozoite Protein
NANP–NVDP repeat region C-terminal amplicon
101 272 293 389
Length = 397 aa
Vaccine construct199
Th2RDV10 Th3R
C-Terminal Amplicon
293–302 311–327 352–363
388
Nanoro
Kintampo
Agogo
Lambaréné
Siaya
Kombewa Kilifi
Korogwe
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ber of days (t) beyond 14 days after the third 
vaccination; and hazard-ratio vaccine efficacy, 
which is defined as one minus the ratio (RTS,S/
AS01 vs. control) of instantaneous incidences of 
the end point under the assumption that inci-
dences (RTS,S/AS01 vs. control) are proportional 
over time. Aalen–Johansen nonparametric maxi-
mum-likelihood estimation with stratification 
according to study site was used to estimate the 
cumulative vaccine efficacy against 3D7-matched 
malaria and 3D7-mismatched malaria, with Wald 
tests used to identify nonzero vaccine efficacy 
and a sieve effect of differential vaccine efficacy. 
Targeted maximum-likelihood estimation36 was 
used to address the same objectives with adjust-
ment for all relevant baseline participant covari-
ates (listed in Table S5 in the Supplementary 
Appendix). The hazard-ratio vaccine efficacy was 
estimated with cause-specific Cox models strati-
fied according to study site, with the use of 
score tests to identify nonzero vaccine efficacy 
and Wald tests for sieve effects.37 The analysis 
methods were selected to be in close alignment 
with those used for assessment of overall vaccine 
efficacy in the original published analyses.4-7 For 
the parasite-positivity end point, we used analy-
sis methods similar to those used for the cumu-
lative vaccine efficacy analysis of the primary 
clinical malaria end point.
Many participants had complex malaria in-
fections generated through multiple parasite 
founder genotypes. Consequently, sieve analyses 
were performed on data sets composed of one 
founder haplotype randomly selected from each 
participant, with “multiple outputation”38 used 
to aggregate results (details are provided in the 
statistical analysis plan). We also performed 
sieve analyses on data sets in which participants 
infected with parasites of one or more founder 
haplotypes were classified as having “any match” 
to 3D7 or “no match” to 3D7.
In addition to investigating the previously 
described Th2R and Th3R epitopes,23 we ana-
lyzed haplotype frequencies in a previously un-
defined genomic region that we designate as 
DV10 (representing 10 amino acid positions, 293 
through 302, bounded by amino acids aspartate 
[D] and valine [V]) and a linkage disequilibrium 
(LD) haplotype based on the 6 positions (314, 
317, 352, 354, 356, and 357) that we found to 
exhibit LD (which we assessed for sites with a 
minor-allele frequency of at least 3% and an r2 of 
at least 0.1) with two or more other positions at 
the five largest study sites (Fig. S9 in the Supple-
mentary Appendix).
All analyses were performed separately for 
each age category. Multiplicity adjustment of 
sieve-effect P values across the epitope haplo-
types and positions was applied separately to the 
two age categories, the two studied proteins 
(circumsporozoite protein and SERA-2), and the 
two measures of vaccine efficacy (cumulative ef-
ficacy and hazard-ratio efficacy). Adjustment for 
family-wise error rate (Holm–Bonferroni39) and 
false discovery rate (Q values; Benjamini–Hoch-
berg40) was applied. Results with Q values of 
0.20 or less for all multiply compared loci or 
unadjusted P values of 0.05 or less for the full 
circumsporozoite protein C-terminal amplicon 
were considered to indicate statistical significance; 
a P value that controlled for the family-wise error 
rate and was 0.05 or less indicated more stringent 
significance. All P values and Q values are two-
sided.
R esult s
Participants and Samples
Fig. 2, and Fig. S2 in the Supplementary Ap-
pendix, summarize sample size and follow-up 
information for the per-protocol group of par-
ticipants who were 5 to 17 months of age; in this 
cohort, P. falciparum genetic data were analyzed 
from 1181 RTS,S/AS01-vaccine recipients and 
909 control-vaccine recipients in whom the pri-
mary clinical malaria end point was confirmed, 
as well as from 284 RTS,S/AS01-vaccine recipi-
ents and 208 control-vaccine recipients in whom 
the parasite-positivity end point was confirmed. 
Fig. S3 and S4 in the Supplementary Appendix 
show this information for the per-protocol group 
of infants who were 6 to 12 weeks of age, and 
Fig. S5 through S8 in the Supplementary Appen-
dix provide information on the samples studied 
for both end points and age categories for the 
NANP–NVDP repeat amplicon.
Complexity of Infection
The majority of samples from participants with 
primary clinical malaria in both age categories 
(68% of samples from infants 6 to 12 weeks of 
age and 65% of samples from children 5 to 17 
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Figure 2. Data Generation and Sample and Data Filtration for the End Point of Primary Clinical Malaria among Children 5 to 17 Months 
of Age.
Vaccine recipients were considered to be out of interval for the dose regimen if they did not receive booster vaccinations according to 
the schedule specified by the trial protocol. The sample cards used were Whatman FTA cards. PCR denotes polymerase chain reaction.
8922 Children underwent randomization
94 Had insufficient
DNA or PCR failure
5948 Were assigned to receive RTS,S/AS01
2974 Were assigned to receive control
vaccine
1371 Were excluded from the per-protocol
population
349 Did not receive 3 doses
570 Received vaccine that had temper-
ature deviation
12 Did not meet inclusion criteria
397 Were out of interval for dose regi-
men
26 Did not have follow-up data after
dose 3
17 Had other reasons
639 Were excluded from the per-protocol
population
126 Did not receive 3 doses
304 Received vaccine that had temper-
ature deviation
10 Did not meet inclusion criteria
171 Were out of interval for dose regi-
men
21 Did not have follow-up data after
dose 3
7 Had other reasons
4577 Were included in the per-protocol
population
3226 Participants
 with nonclinical or
no malaria analyzed
1351 Had primary
clinical malaria
1040 Had primary
clinical malaria
2335 Were included in the per-protocol
population
1329 Sample cards
received
1229 Samples with
DNA sequenced
1181 Participants
with clinical malaria
analyzed
54 Were excluded from
analysis
2 Had PCR contam-
ination
44 Had low-quality
sequence data
8 Had post-vaccina-
tion follow-up after
12 mo
78 Had insufficient
DNA or PCR failure
1018 Sample cards
received
947 Samples with
DNA sequenced
909 Participants
with clinical malaria
analyzed
38 Were excluded from
analysis
26 Had low-quality
sequence data
12 Had post-vaccin-
ation follow-up
after 12 mo
1295 Participants
with nonclinical or
no malaria analyzed
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months of age) had complex infections, defined 
as being founded by two or more distinct para-
site lineages. In the older age category, the dis-
tribution of complexity of infection was shifted 
toward fewer parasite lineages in RTS,S/AS01-
vaccine recipients than in control-vaccine recipi-
ents (complex infections in 61% vs. 71% of 
samples, P<0.001 by Wald test) (Fig. 3A), where-
as in the younger age category there was no evi-
dence of a different distribution between the 
RTS,S/AS01 and control groups (67% and 70%, 
respectively; P = 0.43) (Fig. S10 in the Supplemen-
tary Appendix). This observation for the older 
age category is concordant with findings in two 
phase 2 trials of the related RTS,S/AS02 vac-
cine,31,32 and there were fewer 3D7-matching full-
amplicon haplotypes in infections of high com-
plexity in the RTS,S/AS01-vaccinated group than 
in the control group (Fig. S11 in the Supplemen-
tary Appendix).
Population Variation Profile
We searched for a sieve effect based on perfect 
3D7 match–mismatch in the C-terminal of the 
circumsporozoite protein at three scales: the 
full-amplicon haplotype (95 amino acids), four 
described epitopes or polymorphism cluster 
haplotypes (10 to 17 amino acids apiece), and 
Figure 3. Complexity of Infection and Frequencies of 3D7-Matched Malaria among Children 5 to 17 Months of Age 
with the Primary Clinical Malaria End Point.
The denominator for the frequencies in Panels B through D is the number of samples representing the primary clin‑
ical malaria end point that had sequence data available. Ag denotes Agogo, Ba Bagamoyo, Kil Kilifi, Kin Kintampo, 
Kom Kombewa, Kor Korogwe, La Lambaréné, Li Lilongwe, Na Nanoro, and Si Siaya.
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25 individual polymorphic positions. In the cate-
gory of children 5 to 17 months of age, the fre-
quency of haplotypes with an exact match to the 
3D7 vaccine strain across all polymorphic posi-
tions varied considerably among study sites (Fig. 
3B). In addition, there was a lower frequency of 
3D7-matching haplotypes among RTS,S/AS01-
vaccine recipients than among control vaccine 
recipients, especially at geographic sites with at 
least a 5% frequency of 3D7-matching haplo-
types in the control-vaccine group. Similar dif-
ferences were evident with respect to the epitope 
haplotype frequencies (Fig. 3C). The frequency 
of alleles matching the 3D7 vaccine strain at in-
dividual polymorphic positions was variable (Fig. 
3D). In the category of infants 6 to 12 weeks of 
age, the frequencies of 3D7 matching at all three 
scales in the RTS,S/AS01-vaccinated group were 
similar to those in the control-vaccinated group 
(Fig. S10 in the Supplementary Appendix).
C-Terminal Region Sieve Effects
Through 1 year after vaccination, we detected 
139 clinical malaria cases with a perfect full-
amplicon 3D7 match (Fig. 4A) and 1951 cases 
that were mismatched (Fig. 4B). During this 
period, the cumulative vaccine efficacy against 
clinical malaria with a perfect full-amplicon 3D7 
match was 50.3% (95% confidence interval [CI], 
34.6 to 62.3), and that against mismatched 
clinical malaria was 33.4% (95% CI, 29.3 to 
37.2), with vaccine efficacy significantly higher 
against matched malaria (P = 0.04 by Wald test 
for the sieve effect) (Fig. 4D and Fig. 5A). The 
covariate-adjusted analysis gave almost identical 
results (Table S5 in the Supplementary Appen-
dix). The cumulative vaccine efficacy was higher 
against matched malaria than against mis-
matched malaria throughout the follow-up pe-
riod; for example, during the period through 
month 6, vaccine efficacy against matched ma-
laria was 70.2% (95% CI, 56.1 to 79.8), and that 
against mismatched malaria was 56.3% (95% CI, 
51.1 to 60.9) (P = 0.05 for the sieve effect) (Fig. 
4C). Cumulative vaccine efficacy and sieve ef-
fects for the circumsporozoite protein C-termi-
nal also varied in magnitude among study sites 
when the sites were analyzed individually in the 
older age category (Table S6 in the Supplemen-
tary Appendix).
The hazard-ratio vaccine efficacy over the 12 
months of post-vaccination follow-up was also 
higher against 3D7-matched malaria than against 
3D7-mismatched malaria (62.7% [95% CI, 51.6 
to 71.3] vs. 54.2% [95% CI, 49.9 to 58.1]; P = 0.06 
for the sieve effect) (Fig. 5B, and Table S7 in the 
Supplementary Appendix). The overall vaccine 
efficacy was similar to the efficacy against mis-
matched malaria, because more than 90% of the 
infections were mismatched (Fig. 4D). Post hoc 
analysis defining the haplotypes of a malaria 
case as “any match” or “no match” to 3D7 also 
identified a sieve effect for the circumsporozoite 
protein C-terminal (P<0.001 for the cumulative 
vaccine efficacy sieve effect; P = 0.002 for the 
hazard-ratio vaccine efficacy sieve effect) (Tables 
S8 and S9 in the Supplementary Appendix). In 
contrast, the cumulative and hazard-ratio vac-
cine efficacies were similar against full-ampli-
con–matched malaria and full-amplicon–mis-
matched malaria in the category of infants 6 to 
12 weeks of age (P = 0.58 for the sieve effect) 
(Tables S10 and S11 and Fig. S12 in the Supple-
mentary Appendix), as well as against SERA-2–
matched malaria and SERA-2–mismatched ma-
laria in both age categories (P values for the sieve 
effect >0.30) (Tables S12 through S15 and Fig. 
S13 and S14 in the Supplementary Appendix).
Among the participants who were 5 to 17 
months of age, there were also significant cu-
mulative vaccine efficacy sieve effects (Q value 
≤0.2) for the Th2R and Th3R epitopes, the 
Th2R–Th3R LD haplotype, and the DV10 region 
(Fig. 5A), as well as for the individual amino acid 
positions 299, 301, 317, 354, 356, 359, and 361 
(Table 1). The cumulative vaccine efficacy tended 
to decrease with the number of mismatches with 
3D7 at these seven amino acid positions (Fig. S15 
in the Supplementary Appendix). Hazard-ratio 
analyses of epitopes and regions (Fig. 5B) and 
individual amino acid positions (Table S7 in the 
Supplementary Appendix) yielded differential vac-
cine efficacy results that were consistent with 
those from the cumulative vaccine efficacy analy-
sis, at reduced levels of significance. In the young-
er age category, vaccine efficacy against malaria 
that matched 3D7 at individual circumsporozoite 
protein C-terminal amino acid positions was 
similar to that against malaria with mismatches 
(all Q values >0.20) (Tables S10 and S11 in the 
Supplementary Appendix). No evidence of sieve 
effects was found for individual positions in ei-
ther age category for the SERA-2 locus (Table S12 
through S15 in the Supplementary Appendix).
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For the parasite-positivity end point at 18 
months after dose 3, in the older age category, 
the estimates of vaccine efficacy tended to be 
higher for circumsporozoite protein C-terminal 
3D7-matched malaria than for 3D7-mismatched 
malaria (e.g., vaccine efficacy, 53% vs. 30%; 
P = 0.19 for the full amplicon), although none of 
the differences were significant (Table S16 in the 
Supplementary Appendix). In contrast, there was 
no evidence at all of a sieve effect for the circum-
sporozoite protein C-terminal in the younger age 
category with regard to this end point (Table S17 
in the Supplementary Appendix), and there was 
no evidence of a sieve effect for SERA-2 in either 
age category (Tables S18 and S19 in the Supple-
mentary Appendix).
NANP–NVDP Repeat Region
In 3137 samples representing the clinical ma-
laria end point with sequence data that could be 
evaluated from the B-cell epitope repeat region, 
the NANP–NVDP repeat count ranged from 37 
to 44, with a mode of 40 repeats. There was a 
nonsignificant trend toward declining cumula-
tive vaccine efficacy with increasing NANP–
NVDP repeat count in the older age category 
(P = 0.07) (Fig. S16 in the Supplementary Appen-
dix) and no significant differential vaccine effi-
cacy according to repeat count in the younger 
age category (P = 0.89) (Fig. S17 in the Supple-
mentary Appendix). We did not assess the de-
pendence of vaccine efficacy on NANP–NVDP 
repeat amino acid sequences because the vaccine 
construct contains a truncated repeat region 
(18.5 NANP–NVDP repeats).
Discussion
The discovery that RTS,S/AS01 vaccine efficacy is 
higher against clinical malaria with infections 
matching the 3D7 vaccine construct at epitope 
haplotypes and amino acid positions than it is 
against infections not matching 3D7 is not en-
tirely unexpected, given the polymorphism at 
the C-terminal of the circumsporozoite protein 
antigenic locus and previous observations of al-
lele-specific immune responses to other parasite 
proteins.27,29 This differential cumulative vaccine 
efficacy result could be a false positive result, 
given that the result for the full circumsporozo-
ite protein C-terminal was of borderline signifi-
cance (P = 0.04) and that the analysis of four 
epitopes and 24 amino acid sites gave no Holm–
Bonferroni-adjusted P values below 0.05. How-
ever, 11 of the 28 tests yielded Q values less than 
or equal to 0.20; consequently, we expect at least 
80% of these 11 results to be true positives.
The current study had greater power to detect 
allele-specific protection than did previous eval-
uations of RTS,S in phase 2 trials, because of 
three factors: a larger sample, the inclusion of 
study sites harboring a higher frequency of 3D7-
matching haplotypes, and the use of PCR-based 
next-generation sequencing to resolve the haplo-
types that make up mixed infections. Our main 
result of significant sieve effects for the primary 
clinical malaria end point in the age category of 
5 to 17 months was based on a large sample, 
with measured genetic data from 2145 total 
clinical malaria cases. In contrast, the sieve 
analysis of the parasite-positivity end point in 
participants 5 to 17 months of age, which 
yielded nonsignificant results, had many fewer 
cases (genetic data from 507 total cases). How-
ever, in terms of estimates of vaccine efficacy, 
the sieve effects were slightly stronger for the 
parasite-positivity end point, which suggests 
that the lack of significance could be due to 
lower statistical power rather than to a true lack 
of differential protection. Post hoc power calcu-
lations showed only 30% power to detect the 
23-percentage-point difference between vaccine 
efficacies (53% against malaria matching the 
3D7 circumsporozoite protein C-terminal vs. 
Figure 4 (facing page). Cumulative Incidences and 
 Vaccine Efficacy against the Primary Clinical Malaria 
End Point among Children 5 to 17 Months of Age.
Shown is the cumulative incidence of 3D7‑matched 
malaria (Panel A) and 3D7‑mismatched malaria (Panel B) 
among RTS,S/AS01‑vaccine recipients and control‑vac‑
cine recipients during 12 months of post‑vaccination 
follow‑up, the cumulative vaccine efficacy (one minus 
the ratio [RTS,S/AS01 vs. control] of cumulative inci‑
dences of the first or only episode of clinical malaria 
with a specific haplotype) against 3D7‑matched and 
3D7‑mismatched malaria over the entire post‑vaccina‑
tion follow‑up period (Panel C), and the cumulative 
vaccine efficacy and hazard‑ratio vaccine efficacy (one 
minus the ratio [RTS,S/AS01 vs. control] of instanta‑
neous incidences of the end point under the assump‑
tion that incidences are proportional over time) against 
3D7‑matched and 3D7‑mismatched malaria at 12 months 
after vaccination, with tests for differential haplotype‑
specific vaccine efficacy (Panel D). The I bars in Panel D 
indicate 95% confidence intervals.
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30% against mismatched malaria) with regard 
to the parasite-positivity end point, as compared 
with 51% power to detect such a difference with 
regard to the clinical malaria end point. There-
fore, the selective vaccine protection may have 
operated for both clinical malaria and parasite 
Figure 5. Vaccine Efficacy against the Primary Clinical Malaria End Point among Children 5 to 17 Months of Age.
Shown are the cumulative vaccine efficacy (Panel A) and hazard‑ratio vaccine efficacy (Panel B) for the prevention of clinical malaria in 
which parasites were matches or mismatches with the RTS,S/AS01 vaccine strain (3D7) at each haplotype locus. Estimates were strati‑
fied according to study site. For each haplotype locus, the calculation of haplotype‑matched vaccine efficacy included only clinical ma‑
laria end‑point events with samples in which parasites matched 3D7 at the given locus; the calculation of haplotype‑mismatched vaccine 
efficacy included only clinical malaria end‑point events with samples in which parasites mismatched 3D7 at the given locus. Asterisks 
indicate that the difference in efficacy was significant (Q value ≤0.2 for all 28 multiply compared haplotype loci and unadjusted P≤0.05 
for the full circumsporozoite protein C‑terminal amplicon). FWER denotes family‑wise error rate.
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positivity. In contrast, there was no evidence for 
allele-specific vaccine efficacy in the age catego-
ry of 6 to 12 weeks, despite the significant over-
all protection in this group. This result implies 
a qualitative difference in the vaccine response, 
in addition to the previously reported quantita-
Locus and Amino 
Acid Position† 3D7-Matched Malaria‡ 3D7-Mismatched Malaria‡ Differential Efficacy
Vaccine Efficacy 
(95% CI) P Value
Vaccine Efficacy 
(95% CI) P Value P Value
FWER P 
Value§ Q Value
percent percent
DV10
294 34.8 (30.8 to 38.6) <0.001 31.3 (−6.4 to 55.6) 0.09 0.83 1.00 0.89
295 34.9 (31.0 to 38.6) <0.001 12.6 (−78.8 to 57.2) 0.71 0.44 1.00 0.71
296 34.8 (30.9 to 38.5) <0.001 7.1 (−310.9 to 79.0) 0.92 0.67 1.00 0.89
298 33.5 (29.1 to 37.7) <0.001 41.7 (30.1 to 51.4) <0.001 0.20 1.00 0.41
299¶ 35.4 (31.5 to 39.1) <0.001 −62.8 (−186.0 to 7.3) 0.09 0.003 0.08 0.08
301¶ 49.2 (35.3 to 60.1) <0.001 33.1 (28.9 to 37.0) <0.001 0.03 0.81 0.15
302 34.8 (30.9 to 38.5) <0.001 20.0 (−108.2 to 69.3) 0.64 0.69 1.00 0.89
303 34.6 (30.7 to 38.3) <0.001 68.4 (−100.9 to 95.0) 0.22 0.45 1.00 0.71
Th2R
314‖ 32.7 (26.2 to 38.2) <0.001 37.3 (30.9 to 43.0) <0.001 0.33 1.00 0.61
317¶‖ 45.9 (33.3 to 56.2) <0.001 33.1 (28.9 to 37.1) <0.001 0.06 1.00 0.19
318 36.9 (25.8 to 46.4) <0.001 34.2 (29.8 to 38.4) <0.001 0.65 1.00 0.89
320 34.4 (30.4 to 38.1) <0.001 64.0 (21.0 to 83.6) 0.01 0.14 1.00 0.32
321 35.7 (24.3 to 45.3) <0.001 34.5 (30.1 to 38.7) <0.001 0.85 1.00 0.89
322 34.8 (27.2 to 41.5) <0.001 34.7 (29.4 to 39.6) <0.001 0.99 1.00 0.99
324 37.3 (32.0 to 42.2) <0.001 30.7 (23.3 to 37.4) <0.001 0.16 1.00 0.35
327 35.5 (31.2 to 39.5) <0.001 30.1 (16.5 to 41.4) <0.001 0.42 1.00 0.71
Th3R
349 34.8 (30.9 to 38.5) <0.001 25.4 (−84.1 to 69.8) 0.53 0.81 1.00 0.89
352‖ 35.1 (30.7 to 39.2) <0.001 32.8 (20.0 to 43.5) <0.001 0.73 1.00 0.89
354¶‖ 36.0 (32.0 to 39.8) <0.001 10.8 (−22.6 to 35.1) 0.48 0.05 1.00 0.17
355 34.7 (30.8 to 38.4) <0.001 54.1 (−286.1 to 94.5) 0.47 0.71 1.00 0.89
356¶‖ 36.2 (32.2 to 40.1) <0.001 15.8 (−7.8 to 34.3) 0.17 0.04 0.85 0.15
357‖ 35.3 (27.3 to 42.5) <0.001 34.4 (29.3 to 39.2) <0.001 0.86 1.00 0.89
359¶ 36.1 (32.0 to 40.1) <0.001 22.2 (5.2 to 36.2) 0.01 0.07 1.00 0.20
361¶ 39.3 (33.6 to 44.4) <0.001 29.3 (22.4 to 35.5) <0.001 0.03 0.81 0.15
*  Data are for efficacy through 12 months after vaccination among children 5 to 17 months of age. Estimates were stratified by study site. CI 
denotes confidence interval.
†  Only circumsporozoite protein C‑terminal amino acid positions with a sufficiently high minor‑allele frequency were included in the analysis.
‡  For each amino acid position, the calculation of haplotype‑matched vaccine efficacy included only clinical malaria end‑point events with 
samples in which parasites matched 3D7 at the given position; the calculation of haplotype‑mismatched vaccine efficacy included only clinical 
malaria end‑point events with samples in which parasites mismatched 3D7 at the given position.
§  The family‑wise error rate (FWER) P value is an adjusted39 P value controlling for the FWER.
¶  The differential efficacy was significant; significance was defined as Q value of up to 0.2 for all 28 multiply compared haplotype loci (all epitope 
regions and amino acid positions with a sufficiently high minor‑allele frequency).
‖  The linkage disequilibrium (LD) haplotype includes this amino acid position.
Table 1. Cumulative Vaccine Efficacy against Primary Clinical Malaria.*
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tive difference in anti-circumsporozoite antibody 
titers in the younger age category.4 The biologic 
mechanisms underlying the differences between 
the age categories remain to be elucidated, but 
they could include a role of maternal antibody, 
interactions with other vaccine responses, or dif-
ferences in immune-response capacity between 
infants and children. Further immunologic anal-
yses could clarify the mechanisms of selective 
versus nonselective vaccine-induced immunity.
Genetic surveillance of circumsporozoite pro-
tein sequences in parasite populations could in-
form the development of future vaccine candi-
dates targeting polymorphic malaria parasite 
proteins. The genotype-specific vaccine efficacy 
results we report here complement previous es-
timates of RTS,S/AS01 efficacy in this phase 3 
trial; the previously reported 12-month hazard-
ratio vaccine efficacy of 55.8% against clinical 
malaria among children 5 to 17 months of age4 
can now be interpreted as a multiplicative 
weighted mean of hazard-ratio vaccine efficacy 
values of 62.7% against matched parasites (139 
infections) and 54.2% against mismatched para-
sites (1951 infections) (Fig. 5B). The observed 
variation among study sites in infections with a 
perfect vaccine match in the circumsporozoite 
protein C-terminal (Fig. 3B, and Fig. S18 and S19 
in the Supplementary Appendix) may help to 
explain previously reported variation in overall 
vaccine efficacy among study sites, although the 
magnitude of this contribution is expected to be 
low because of the overall rarity of the 3D7 hap-
lotype.6 Broader deployment of the vaccine could 
result in increased selection on the 3D7 haplo-
type or its component epitopes and amino acid 
alleles. Sieve analysis of next-generation sequenc-
ing data constitutes an approach for understand-
ing partial vaccine efficacy.
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